← Leaderboards
Krista F Huybrechts
Brigham And Women'S Hospital
$10,039,261
Attributed
$16,117,432
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2013–25$5M$3.8M$2.5M$1.3M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,117,432 · 7
By mechanism
R01$15,043,048 · 5
K01$882,360 · 1
R03$192,024 · 1
Top collaborators
- Brian Thomas Bateman11 shared
- Shirley Wang9 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Xin Wang$1,305,601
- Brian Thomas Bateman$6,450,805
- S Bryn Austin$5,982,084
- Nicole Prince$355,482
- Shirley Wang$7,765,582
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsCohortSafetyWomanDatabasesPublic HealthPregnancyPregnant WomenNeonatal OutcomeMental HealthMedication SafetyProspectiveScanningBaseMental DisordersMedicaidComparativeCongenital AbnormalityChildEpidemiologic MethodsDesignReportingHealth Care Service UtilizationData Sources
Grant awards (32)
The Comparative Effectiveness and Safety of Pharmacotherapies for the Treatment of Opioid Use Disorder in Pregnancy$763,288
R01 · FY2025 · DA · contact PI
Safety of Benzodiazepines and Non-Benzodiazepine Sedative Hypnotics in Pregnancy$620,426
R01 · FY2025 · HD · contact PI
Active Surveillance of the Safety of Antipsychotic Medications in Pregnancy$532,996
R01 · FY2025 · HD · contact PI
TreeScan to Evaluate the Safety of New Drugs in Pediatric Populations$512,645
R01 · FY2025 · HD
The Comparative Effectiveness and Safety of Pharmacotherapies for the Treatment of Opioid Use Disorder in Pregnancy$839,898
R01 · FY2024 · DA · contact PI
Safety of Benzodiazepines and Non-Benzodiazepine Sedative Hypnotics in Pregnancy$613,470
R01 · FY2024 · HD · contact PI
Active Surveillance of the Safety of Antipsychotic Medications in Pregnancy$526,905
R01 · FY2024 · HD · contact PI
TreeScan to Evaluate the Safety of New Drugs in Pediatric Populations$507,519
R01 · FY2024 · HD
The Comparative Effectiveness and Safety of Pharmacotherapies for the Treatment of Opioid Use Disorder in Pregnancy$688,134
R01 · FY2023 · DA · contact PI
Safety of Benzodiazepines and Non-Benzodiazepine Sedative Hypnotics in Pregnancy$620,426
R01 · FY2023 · HD · contact PI
TreeScan to Evaluate the Safety of New Drugs in Pediatric Populations$611,543
R01 · FY2023 · HD
Active Surveillance of the Safety of Antipsychotic Medications in Pregnancy$532,996
R01 · FY2023 · HD · contact PI
The Comparative Effectiveness and Safety of Pharmacotherapies for the Treatment of Opioid Use Disorder in Pregnancy$688,134
R01 · FY2022 · DA · contact PI
Safety of Benzodiazepines and Non-Benzodiazepine Sedative Hypnotics in Pregnancy$678,853
R01 · FY2022 · HD · contact PI
TreeScan to Evaluate the Safety of New Drugs in Pediatric Populations$626,758
R01 · FY2022 · HD
In-utero exposure to psychotropic medications and the risk of neurodevelopmental disorders$539,371
R01 · FY2022 · MH · contact PI
Active Surveillance of the Safety of Antipsychotic Medications in Pregnancy$532,227
R01 · FY2022 · HD · contact PI
The Comparative Effectiveness and Safety of Pharmacotherapies for the Treatment of Opioid Use Disorder in Pregnancy$701,082
R01 · FY2021 · DA · contact PI
Active Surveillance of the Safety of Antipsychotic Medications in Pregnancy$552,746
R01 · FY2021 · HD · contact PI
In-utero exposure to psychotropic medications and the risk of neurodevelopmental disorders$539,371
R01 · FY2021 · MH · contact PI
The Comparative Effectiveness and Safety of Pharmacotherapies for the Treatment of Opioid Use Disorder in Pregnancy$737,855
R01 · FY2020 · DA · contact PI
In-utero exposure to psychotropic medications and the risk of neurodevelopmental disorders$571,591
R01 · FY2020 · MH · contact PI
Postpartum Opioid Related Mortality in Medicaid Patients$268,441
R01 · FY2020 · DA · contact PI
In-utero exposure to psychotropic medications and the risk of neurodevelopmental disorders$571,591
R01 · FY2019 · MH · contact PI
In-utero exposure to psychotropic medications and the risk of neurodevelopmental disorders$664,782
R01 · FY2018 · MH · contact PI
Ondansetron and risk of congenital malformations$96,043
R03 · FY2018 · HD · contact PI
Improved methods to assess the comparative safety of new psychiatric medications$176,472
K01 · FY2017 · MH · contact PI
Ondansetron and risk of congenital malformations$95,981
R03 · FY2017 · HD · contact PI
Improved methods to assess the comparative safety of new psychiatric medications$176,472
K01 · FY2016 · MH · contact PI
Improved methods to assess the comparative safety of new psychiatric medications$176,472
K01 · FY2015 · MH · contact PI
Improved methods to assess the comparative safety of new psychiatric medications$176,472
K01 · FY2014 · MH · contact PI
Improved methods to assess the comparative safety of new psychiatric medications$176,472
K01 · FY2013 · MH · contact PI